Jeffrey Bluestone Healthcare News

This is selected healthcare news for Jeffrey Bluestone, which is filed under People. There are 21 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
8/24/2022 ‘Treg’ startup Sonoma expands with plans for manufacturing plant | BioPharma Dive
... testing for its medicines, which are designed to treat rheumatoid arthritis, inflammatory bowel disease and other as-yet unspecified conditions. Launched by well-known immunology Jeffrey Bluestone, the biotech has raised more than $335 million to date . It's one of a handful of startups exploring Tregs, which have also ...
BioPharma Dive
4/13/2022 Versant-backed startup launches with plans to broaden cell therapy’s reach
... Called Cimeio Therapeutics , the new company is led by a team of pharmaceutical industry veterans and an advisory board filled with scientific luminaries, including immunologist Jeffrey Bluestone and gene editing pioneer Fyodor Urnov. Cimeio's approach involves "shielding" transplanted cells by genetically editing them in ways that allows paired immunotherapies to ...
BioPharma Dive
9/16/2021 Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary
... of the company. ‚AuWe are delighted to welcome Doug to the team as we continue this period of rapid growth as a company,‚Au said Jeffrey Bluestone, Ph.D., Co-founder and CEO of Sonoma Biotherapeutics. ‚AuHis decades of biopharma legal experience will bring valuable insights that will be critical as ...
Business Wire
8/4/2021 Sonoma Bio bags $265M to rev up cell therapies for arthritis, diabetes
... rheumatoid arthritis. Its cell therapies are based on regulatory T cells, or Tregs, which identify unwanted inflammatory and autoimmune responses and shut them down, said Jeffrey Bluestone, Ph.D., CEO and co-founder of Sonoma Bio. Since its launch, the company has added another $30 million to a series A round ...
FierceBiotech
2/6/2020 Sonoma Bio debuts with $40M to push Treg treatments for autoimmune, neuro diseases
Sonoma Biotherapeutics launched with a mission to create regulatory T-cell treatments for autoimmune and neurodegenerative diseases, $40 million in series A financing and renowned immunologist, Jeffrey Bluestone, Ph.D., at its helm. Bluestone lands at Sonoma after leading the Parker Institute for Cancer Immunotherapy as its president and CEO. He's ...
FierceBiotech
2/6/2020 Sonoma Biotherapeutics Launches With $40 Million In Series A Funding To Advance Regulatory T Cell Therapy In Autoimmune And Degenerative Diseases - TheStreet
... safe, effective and long-lasting treatments for a range of conditions where current drugs and biologics are simply not good enough," said founder and CEO Jeffrey Bluestone , PhD. "As the immune system's master regulators of protecting the body against self-destruction, Treg cell therapy is perhaps the ideal means to ...
TheStreet
2/6/2020 Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases
Biotech Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases By Matthew Herper @matthewherper February 6, 2020 Immunologist Jeff Bluestone Courtesy Sonoma Jeffrey Bluestone, the prominent immunologist, has decided to leave his position as president of the Parker Institute for Cancer Immunotherapy, the research ...
STAT
1/14/2020 Opinion: Innovation in biotech R&D: New resources offer new hope
... we conduct it. I'll start with the finance side of the equation. The center of gravity, as always, is the federal government. Two years ago, Jeffrey Bluestone, Laurie Glimcher, and I argued in STAT that the National Institutes of Health risked losing its edge in biomedical innovation. Since then, the ...
STAT
5/10/2019 The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research
The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research A Conversation With Jeffrey Bluestone, PhD By Jo Cavallo November 25, 2016 Advertisement The greatest challenge to individual scientists today is bringing together all the resources necessary to address the most challenging questions in immunotherapy. We are committed ...
ascopost.com
5/10/2019 How the Nobel Prize Could Spur More Cancer Advances
... Berkeley, Dr. Allison demonstrated that the molecule CD28 is the “gas pedal” that T cells need for activation. In 1994, Dr. Allison and another investigator, Jeffrey Bluestone, PhD [now President and Chief Executive Officer of the Parker Institute for Cancer Immunotherapy and the A.W. and Mary -Margaret Clausen Distinguished Professor ...
ascopost.com
5/10/2019 Advancing Immune Checkpoint Targeting in Cancer Treatment
... second molecule on the surface of T cells, called CD28, which acts as the T cell's gas pedal, accelerating immune response. He and another investigator, Jeffrey Bluestone, PhD , Executive Vice Chancellor and Provost at the University of California, San Francisco, performed independent experiments and identified CTLA-4 as an inhibitory ...
ascopost.com
10/31/2017 BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies
... that "the hope is that, using this novel treatment strategy, we could minimize or entirely spare patients from lifelong immunosuppressive treatments and their side effects." Jeffrey Bluestone, PhD, the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Director of the Hormone Research Institute in the Diabetes ...
PR Newswire
10/31/2017 BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials
... that "the hope is that, using this novel treatment strategy, we could minimize or entirely spare patients from lifelong immunosuppressive treatments and their side effects." Jeffrey Bluestone, PhD, the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Director of the Hormone Research Institute in the Diabetes ...
PR Newswire